Publication:
Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.

Simple item page
dc.contributor.authorİNANÇ, GÜZİDE NEVSUN
dc.contributor.authorsInanc N., Kostov B., Priori R., Flores-Chavez A., Carubbi F., Szántó A., Valim V., Bootsma H., Praprotnik S., Fernandes Moça Trevisani V., et al.
dc.date.accessioned2022-12-28T15:49:36Z
dc.date.available2022-12-28T15:49:36Z
dc.date.issued2022-12-01
dc.description.abstractObjective To investigate the safety and efficacy of SARS-Cov-2 vaccination in patients with primary Sjögren syndrome (pSS) due to scarcity of data in this population. Methods By the first week of May 2021, all Big Data SS Consortium centres patients who had received at least one dose of any SARS-CoV-2 vaccine were included in the study. The in-charge physician asked patients about local and systemic reactogenicity to collect SARS-CoV-2 vaccination data. Results The vaccination data of 1237 patients were received. A total of 835 patients (67%) reported any adverse events (AEs), including local (53%) and systemic (50%) AEs. Subjective symptoms (63%) were the most common local AEs, followed by objective signs at the injection site (16%), and general symptoms were the most commonly reported systemic AEs (46%), followed by musculoskeletal (25%), gastrointestinal (9%), cardiopulmonary (3%), and neurological (2%). In addition, 141 (11%) patients reported a significant worsening/ exacerbation of their pre-vaccination sicca symptoms and fifteen (1.2%) patients reported active involvement in the glandular (n=7), articular (n=7), cutaneous (n=6), pulmonary (n=2), and peripheral nervous system (n=1) domains due to post-vaccination SS flares. In terms of vaccination efficacy, breakthrough SARS-CoV-2 infection was confirmed after vaccination in three (0.24 %) patients, and positive anti-SARS-Cov-2 antibodies were detected in approximately 95% of vaccinated SS patients, according to data available. Conclusion Our data suggest that patients with pSS develop adequate humoral response and no severe AEs after SARS-CoV-2 vaccination and therefore raise no concerns about the vaccine’s efficacy or safety profile in this population.
dc.identifier.citationInanc N., Kostov B., Priori R., Flores-Chavez A., Carubbi F., Szántó A., Valim V., Bootsma H., Praprotnik S., Fernandes Moça Trevisani V., et al., "Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.", Clinical and experimental rheumatology, cilt.40, sa.12, ss.2290-2297, 2022
dc.identifier.doi10.55563/clinexprheumatol/dt6klo
dc.identifier.endpage2297
dc.identifier.issn0392-856X
dc.identifier.issue12
dc.identifier.startpage2290
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/36bfdf1b-444f-4162-9961-e4c9b212bc2f/file
dc.identifier.urihttps://hdl.handle.net/11424/284564
dc.identifier.volume40
dc.language.isoeng
dc.relation.ispartofClinical and experimental rheumatology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectprimary Sjögren syndrome
dc.subjectSARS-CoV-2 vaccination
dc.subjectSjögren Big Data Consortium
dc.subjectadverse events
dc.subjectdisease flare
dc.titleSafety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.
dc.typearticle
dspace.entity.typePublication
local.avesis.id36bfdf1b-444f-4162-9961-e4c9b212bc2f
local.indexed.atPUBMED
relation.isAuthorOfPublicationc963a17b-4775-4dd7-8db7-ea072cc49ef1
relation.isAuthorOfPublication.latestForDiscoveryc963a17b-4775-4dd7-8db7-ea072cc49ef1

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
769.47 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs